598 / 1631
Frontline Ibrutinib + Rituximab
Follicular Lymphoma
•
Objectives
–
Primary
•
Evaluate the ORR (CR+PR)
–
Secondary
•
Duration of response, PFS
•
Safety
Untreated
Follicular
Lymphoma
N=60
Rituximab
375mg IV x 4
Ibrutinib
560 mg PO Daily
91